Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC002 in CLDN18.2-positive Advanced Digestive System Tumors
NCT05946226Phase 1Recruiting
- Sponsor
- Immunofoco
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of claudin 18.2 CAR-T in gastric cancer (GC), esophagogastric junction adenocarcinoma (GEJA), pancreatic cancer (PC) and 1 more, sponsored by Immunofoco. Primary endpoint: Incidence and severity of dose-limiting toxicity at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
claudin 18.2 CAR-T
03
Conditions
gastric cancer (GC)esophagogastric junction adenocarcinoma (GEJA)pancreatic cancer (PC)digestive system neoplasms
Beyond the preview
Go deeper on NCT05946226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946226.